orexin 2 receptor agonist 2

Orexin 2 Receptor Agonist 2 (ORA-2) is a specific agonist for the orexin 2 receptor.

Orexin 2 Receptor Agonist 3 is an orally active and brain-penetrant agonist of the orexin receptor 2 (OX2) with an EC50 value of 2.5 nM. This compound increases wakefulness in both orexin/ataxin-3 NT1 mouse models and healthy Beagle dogs. It is applicable for research related to narcolepsy.

Orexin 2 Receptor Agonist (OX2R) is an effective (EC50: 23 nM) and OX2R-selective (OX1R/OX2R EC50 ratio: 70) agonist.

Suntinorexton (TAK 861) is an orexin type 2 receptor (OX2R) agonist for the study of neurological disorders.

Oveporexton is an agonist for the type 2 orexin receptor (OX2R).

Alixorexton is an agonist of the orexin-2 receptor (orexin-2 receptor) and is utilized in obesity research.

OX2R-IN-2 (compound 63c) is an agonist of the type 2 orexin receptor (OX2R) with an EC50 value of 339 nM. It can cross the blood-brain barrier and exhibits no cytotoxicity.

Potent and selective orexin OX2 receptor agonist (EC50 = 28 nM at human OX2 expressed in CHO cells). Displays approximately 100-fold selectivity for OX2 over OX1 (EC50 = 2.75 μM at human OX1 expressed in CHO cells). Depolarizes OX2-expressing histaminergic neurons in mouse brain slices. Increases wake time in wild type mice. Suppresses cataplexy-like symptoms in OX knockout mice. Nagahara et al (2015) Design and synthesis of non-peptide, selective orexin receptor 2 agonists. J.Med.Chem. 58 7931 PMID:26267383 |Irukayama-Tomobe et al (2017) Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proc.Natl.Acad.Sci.USA. 144 5731 PMID:28507129

YNT-185 is a nonpeptide, selective agonist of the orexin type-2 receptor (OX2R), with EC50 values of 0.028 μM for OX2R and 2.75 μM for OX1R. Additionally, YNT-185 effectively alleviates symptoms of narcolepsy-cataplexy in mouse models.

Firazorexton is a potent orexin type 2 receptor (OX2R) agonist.

[Ala11,D-Leu15]-Orexin B(human) TFA is a potent, selective agonist for the orexin-2 receptor (OX2), demonstrating 400-fold higher selectivity for OX2 (EC50=0.13 nM) compared to the orexin-1 receptor (OX1) with an EC50 of 52 nM.

OXA(17-33) TFA is a potent and selective agonist for the orexin-1 receptor (OX1), with approximately 23-fold higher affinity for OX1 (EC50 = 8.29 nM) compared to the orexin-2 receptor (OX2) (187 nM) [1].

Orexin B, rat, mouse (Rat orexin B) TFA, an endogenous agonist for orexin receptors, binds to and activates the orphan G protein-coupled receptors OX1-R and OX2-R, playing a crucial role in stimulating food intake, increasing energy expenditure, and regulating sleep-wake cycles [1] [2] [3].

Firazorexton hydrate (TAK-994) is a brain-penetrant, orally active agonist of the orexin type 2 receptor (OX2R) with a potent EC50 of 19 nM, effectively reducing wakefulness fragmentation and cataplexy-like episodes in mouse models of narcolepsy [1].

OX2R-IN-3 (Compound 53) functions as an orally active agonist for the type 2 orexin receptor (OX2R), exhibiting an EC50 value of less than 100 nM [1].

[Ala11,D-Leu15]-Orexin B acetate is a selective agonist of orexin-2 receptor (OX2) with an EC50 of 0.13 nM, showing 400-fold selectivity over OX1 (52 nM).